.Effect of N-acetylcysteeine on non-alcoholic fatty liver disease

Investigation of the effect of N-acetylcysteine on serum liver enzymes and metabolic profiles in patients with non-alcoholic fatty liver disease

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201220049772N1

Enrollment

Registered

2021-02-20

Start date

2021-02-19

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic fatty liver_N acetyle cysteine. Non-alcoholic fatty liver

Interventions

Intervention 1: Intervention group: In this study, N-acetylcysteine ??tablets made by Osweh Company with a dose of 600 mg, 3 tablets for 8 weeks of intervention will be used. Intervention 2: Control g

Eligibility

Sex/Gender

All

Age

25 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients with non-alcoholic fatty liver disease based on diagnostic criteria Age 25 to 75 years No smoking

Exclusion criteria

Exclusion criteria: Having any acute and active infection Consumption of any kind of supplement (vitamins, minerals, etc.) by the patient during the last 3 months Severe renal failure (eGFR less than 30 ml / min) Severe liver failure Diabet mellitus Hyperlipidemia requires medical treatment

Design outcomes

Primary

Measure	Time frame
Primary outcome variables in this study include insulin resistance. Timepoint: Calculation of insulin resistance at the beginning of the study and eight weeks after starting N acetylcysteine. Method of measurement: The Index-HOMA formula is used to calculate insulin resistance, which is the product of serum insulin (ml /µIU) multiplied by fasting plasma glucose (dL / mg) divided by 405.	—

Secondary

Measure	Time frame
Serum levels of liver enzymes. Timepoint: At the beginning of the study and eight weeks after starting to take N-acetylcysteine. Method of measurement: Enzymatically using an autoanalyzer.;Metabolic profiles (fasting plasma glucose, fasting serum cholesterol, fasting serum triglyceride). Timepoint: At the beginning of the study and eight weeks after starting to take N-acetylcysteine. Method of measurement: Serum total cholesterol, C-LDL, C-HDL and triglyceride concentrations are measured enzymatically using an autoanalyzer. Determination of fasting blood sugar using glucose oxidase / peroxidase method Pars Azmoun Company, Tehran, Iran).	—

Measure

Time frame

Serum levels of liver enzymes. Timepoint: At the beginning of the study and eight weeks after starting to take N-acetylcysteine. Method of measurement: Enzymatically using an autoanalyzer.;Metabolic profiles (fasting plasma glucose, fasting serum cholesterol, fasting serum triglyceride). Timepoint: At the beginning of the study and eight weeks after starting to take N-acetylcysteine. Method of measurement: Serum total cholesterol, C-LDL, C-HDL and triglyceride concentrations are measured enzymatically using an autoanalyzer. Determination of fasting blood sugar using glucose oxidase / peroxidase method Pars Azmoun Company, Tehran, Iran).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSinaeinejhad mehrdad

Kashan University of Medical Sciences

mehrdad.sinaeinejhad@gmail.com00983155540026-9

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026